EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer

Zilong Zhu, Zhuze Chu, Fei Fei, Chenxi Wu, Zhengyue Fei, Yuxia Sun, Yun Chen iD, Peihua Lu iD

Vaccines · 13.01.2025 · 13 (1) · 64

DOI: 10.3390/vaccines13010064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 13.01.2025. Verfasst von Zilong Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 21…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Program of Wuxi Medical Center, Nanjing Medical University, General Program of Wuxi Health Committee, Top Talent Support Program for young and middle-aged people of Wuxi Health Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the past decade, immunotherapy has become a major choice for the treatment of lung cancer, yet its therapeutic efficacy is still relatively limited due to the various immune escape mechanisms of tumors. Based on this, we introduce Neo-BCV, a novel bacterial composite vaccine designed to enhance immune responses against lung cancer.

Methods

We investigated the immune enhancing effect of Neo-BCV through in vivo and in vitro experiments, including flow cytometry, RNA-seq, and Western blot.

Results

We have demonstrated that Neo-BCV can promote Dendritic cells (DCs) maturation and induce DCs differentiation into pro-inflammatory subgroups, significantly enhancing cytotoxic T lymphocyte (CTL)-mediated anti-tumor responses. Transcriptome sequencing revealed that Neo-BCV exerts its effects by specifically inhibiting the JAK2-STAT3 signaling pathway, a crucial regulator of cancer progression, metabolism, and inflammation. Moreover, Neo-BCV significantly improved the immune microenvironment in both tumor and spleen tissues without inducing notable toxic effects in major organs.

Conclusions

These findings highlight Neo-BCV’s potential as a safe and effective therapeutic strategy, offering a novel avenue for clinical translation in lung cancer immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

JAK2-STAT3 signalingdendritic cellsnon-small cell lung cancertumor vaccines

Autor:innen und Institutionen

  • The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.

ORCID-Profile: Yun Chen, Peihua Lu

Förderung

  • General Program of Wuxi Medical Center, Nanjing Medical University
  • General Program of Wuxi Health Committee
  • Top Talent Support Program for young and middle-aged people of Wuxi Health Committee

Zitieren

APA

Zhu, Z., Chu, Z., Fei, F., Wu, C., Fei, Z., Sun, Y., Chen, Y., & Lu, P. (2025). Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer. Vaccines, 13(1), 64. https://doi.org/10.3390/vaccines13010064

Vancouver

Zhu Z, Chu Z, Fei F, Wu C, Fei Z, Sun Y, et al. Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer. Vaccines. 2025;13(1):64. doi:10.3390/vaccines13010064

BibTeX
@article{Zhu2025,
  author = {Zhu, Zilong and Chu, Zhuze and Fei, Fei and Wu, Chenxi and Fei, Zhengyue and Sun, Yuxia and Chen, Yun and Lu, Peihua},
  title = {Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {64},
  doi = {10.3390/vaccines13010064}
}
Kostenlos starten →